Drug Profile
Nitric oxide - Mallinckrodt
Alternative Names: Ik 7001; IK-3001; IK-7001; INOflo; INOmax; INOmax Total Care; INOMAX® Total Care package; INOtherapy; INOVENTLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital
- Developer AGA Linde Healthcare; Ikaria Holdings; Mallinckrodt plc; Massachusetts General Hospital
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypoxic respiratory failure; Pulmonary hypertension
- Phase III Bronchopulmonary dysplasia
- Preclinical SARS-CoV-2 acute respiratory disease
- No development reported Transplant rejection
- Discontinued Heart failure; Pulmonary arterial hypertension; Reperfusion injury
Most Recent Events
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in SARS-COV-2 acute respiratory disease in USA (Inhalation, Inhalant)
- 28 May 2023 No recent reports of development identified for preclinical development in Transplant-rejection in USA (Parenteral, Liquid)
- 30 Dec 2022 Mallinckrodt Pharmaceuticals has patent protection for INOmax® in USA